EA201992644A1 - SOLID PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN ETHEXILATE FOR ORAL USE - Google Patents

SOLID PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN ETHEXILATE FOR ORAL USE

Info

Publication number
EA201992644A1
EA201992644A1 EA201992644A EA201992644A EA201992644A1 EA 201992644 A1 EA201992644 A1 EA 201992644A1 EA 201992644 A EA201992644 A EA 201992644A EA 201992644 A EA201992644 A EA 201992644A EA 201992644 A1 EA201992644 A1 EA 201992644A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
solid pharmaceutical
ethexilate
dabigatran
oral use
Prior art date
Application number
EA201992644A
Other languages
Russian (ru)
Inventor
Али Тюркильмаз
Арзу Палантёкен
Эзель Ураз
Йилдиз Гюлькок
Original Assignee
Сановель Илач Санайи Ве Тиджарет Аноним Ширкети
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64559741&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992644(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сановель Илач Санайи Ве Тиджарет Аноним Ширкети filed Critical Сановель Илач Санайи Ве Тиджарет Аноним Ширкети
Priority claimed from PCT/TR2018/050221 external-priority patent/WO2019004980A2/en
Publication of EA201992644A1 publication Critical patent/EA201992644A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к твердым фармацевтическим композициям для перорального применения, содержащим дабигатрана этексилат в виде свободного основания или в виде его фармацевтически приемлемых солей, полиморфов, сольватов, гидратов или сложных эфиров.The present invention relates to solid pharmaceutical compositions for oral administration containing dabigatran etexilate in the form of the free base or in the form of its pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters.

EA201992644A 2017-05-10 2018-05-10 SOLID PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN ETHEXILATE FOR ORAL USE EA201992644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2017/06848A TR201706848A2 (en) 2017-05-10 2017-05-10 SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING DABIGATRAN ETEXCLATE
TR2018/06309A TR201806309A2 (en) 2017-05-10 2018-05-04 Solid oral pharmaceutical compositions of dabigatran etexilate
PCT/TR2018/050221 WO2019004980A2 (en) 2017-05-10 2018-05-10 Solid oral pharmaceutical compositions of dabigatran etexilate

Publications (1)

Publication Number Publication Date
EA201992644A1 true EA201992644A1 (en) 2020-04-07

Family

ID=64559741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992644A EA201992644A1 (en) 2017-05-10 2018-05-10 SOLID PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN ETHEXILATE FOR ORAL USE

Country Status (8)

Country Link
EP (2) EP3634388A2 (en)
AU (1) AU2018293361B2 (en)
BR (1) BR112019023781A2 (en)
CO (1) CO2019013649A2 (en)
EA (1) EA201992644A1 (en)
NZ (1) NZ759901A (en)
TR (2) TR201706848A2 (en)
WO (1) WO2019004979A2 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
US20130177652A1 (en) * 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
RS62566B1 (en) * 2012-02-21 2021-12-31 Towa Pharmaceutical Europe S L Oral pharmaceutical compositions of dabigatran etexilate
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN104784147B (en) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 A kind of dabigatran etexilate methanesulfonate pharmaceutical capsules composition and preparation method thereof
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
EP2929884A1 (en) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
CN104095830A (en) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 Preparation method for mesylate dabigatran capsule
CN105560206A (en) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 Preparation of Pradaxa capsule
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor
IN2015CH01145A (en) * 2015-03-09 2016-09-16

Also Published As

Publication number Publication date
BR112019023781A2 (en) 2020-06-02
AU2018293361B2 (en) 2021-09-16
TR201806309A2 (en) 2018-11-21
EP3634388A2 (en) 2020-04-15
WO2019004979A3 (en) 2019-04-11
NZ759901A (en) 2021-12-24
AU2018293361A1 (en) 2020-01-02
TR201706848A2 (en) 2018-11-21
EP3621599A2 (en) 2020-03-18
WO2019004979A2 (en) 2019-01-03
CO2019013649A2 (en) 2020-05-15

Similar Documents

Publication Publication Date Title
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
MX2020004932A (en) Compounds useful for inhibiting cdk7.
EA201691302A1 (en) NEW HETEROCYCLIC COMPOUNDS
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
TR201906325T4 (en) Tetrazolone substituted dihydropyridinone MGAT2 inhibitors.
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
PH12019501639A1 (en) Jaki selective inhibitors
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
EA201792374A1 (en) AZABENZIMIDAZOLES AND THEIR APPLICATION AS AMPA RECEPTOR MODULATORS
CY1124251T1 (en) CARBOXAMIDE DERIVATIVES
IN2013CH05441A (en)
EA202092829A1 (en) CONTROLLED RELEASE TOPACITINIB COMPOSITIONS
IN2014MN02245A (en)
MX2020011756A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same.
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
EA201791480A1 (en) NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHARMONAL AGENTS
TR201819805T4 (en) FLAVAGLIN DERIVATIVES.
WO2019004980A3 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
CY1123185T1 (en) INDOLE DERIVATIVES
TR201714882A2 (en) Topical pharmaceutical compositions of luliconazole
EA201991045A1 (en) CONDENSED ASAGETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS AMPA RECEPTOR MODULATORS
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
EA201992644A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS BASED ON DABIGATRAN ETHEXILATE FOR ORAL USE
BR112018003335A2 (en) pharmaceutical compositions comprising 3- (5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl) -piperidine-2,6-dione
TR201722323A2 (en) Oral pharmaceutical compositions of dabigatran